Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II Study of Sequential Non-Cross-Resistant Chemotherapy in Gastro-esophageal Adenocarcinoma
2014-003039-20Phase 2Completed
- Sponsor
- ASST Cremona
- Start
- Sep 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of docetaxel, cisplatin, fluorouracil, oxaliplatin, irinotecan and 1 more in gastric adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by ASST Cremona. Primary endpoint: Progression-free survival. Started Sep 2014; status: completed.
02
Drugs
docetaxelcisplatinfluorouraciloxaliplatinirinotecan
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2014-003039-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003039-20.